These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31689604)

  • 1. A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients.
    Yu JK; Iorio A; Chelle P; Edginton AN
    Thromb Res; 2019 Dec; 184():31-37. PubMed ID: 31689604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to extended half-life products in Canada - preliminary data.
    Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
    Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
    [No Abstract]   [Full Text] [Related]  

  • 5. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients.
    Bukkems LH; Heijdra JM; Mathias M; Collins PW; Hay CRM; Tait RC; Mangles S; Myers B; Evans G; Bailiff B; Curry N; Payne J; Austin S; Goedhart TMHJ; Leebeek FWG; Meijer K; Fijnvandraat K; Chowdary P; Mathôt RAA; Cnossen MH;
    Thromb Haemost; 2020 May; 120(5):747-757. PubMed ID: 32369846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
    Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eloctate for hemophilia A.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):143-4. PubMed ID: 26445206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extended protection with Efmoroctocog alfa].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27462665
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.
    Kremer Hovinga ICL; Schutgens REG; van der Valk PR; van Vulpen LFD; Mauser-Bunschoten EP; Fischer K
    Haemophilia; 2018 Jul; 24(4):e280-e283. PubMed ID: 30044044
    [No Abstract]   [Full Text] [Related]  

  • 10. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.
    Hajducek DM; Chelle P; Hermans C; Iorio A; McEneny-King A; Yu J; Edginton A
    Haemophilia; 2020 May; 26(3):384-400. PubMed ID: 32281726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIII Fc for the treatment of haemophilia A.
    Hermans C; Mancuso ME; Nolan B; Pasi KJ
    Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
    Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
    Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
    Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.